Australian Homeland Security Research Centre
Athol Yates, Executive Director www.homelandsecurity.org.au

The Australian Homeland Security Research Centre undertakes independent, evidence-based analysis of domestic security issues and has a pandemic influenza research program.

Virogard
Jim Gault
www.virogard.com

Virogard Pty Ltd has developed an entirely new antimicrobial personal protective mask aimed at replacing the ‘surgical mask’ in common use and also conventional P2 or N95 particulate respirators. Practical cost-effective protection from airborne bacteria and viruses is becoming a significant issue in a world susceptible to contagious diseases such as SARS and pandemic influenza.

The reusable VIROGARD mask has an ergonomic fit so that is can be worn without discomfort for long periods. It is simple to fit and wear. More importantly the mask has unique features that enhance protection – an oil/water repellent and a permanent antimicrobial coating that is entirely safe for humans but kills bacteria and viruses [including Influenza Type A] on contact.

This Australian development is available now and attracting considerable international interest.

CRG Healthcare

Presentation

Keith Wilson and Dr Nenad Firez
www.CRGhealthcare.com

CRG Healthcare is a subsidiary of Clean Room Garments Pty Ltd. CRG has been the market leader in contamination and infection control solutions for over 35 years. Personal protective equipment (PPE) is a well established area of expertise within CRG Healthcare, with particular emphasis on the customised supply, packaging, storage and training of pandemic related PPE for the Australian and NZ Federal Governments and various Australian corporations.

Visit www.CRGhealthcare.com.au for comprehensive pandemic influenza information, relevant website links and customisable kit contents, with flexible schemes to suit your company’s needs, budget and storage requirements.

Roche

Presentation

Trevor Thornell
www.roche-australia.com

Roche is a leading healthcare company with a uniquely broad spectrum of innovative solutions. For more than 100 years, Roche has been active in the discovery, development, manufacture and marketing of novel healthcare solutions. Roche products and services address prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life.

Draeger Safety

Presentation

Mary Limnios
www.draeger.com

Dräger Safety AG & Co. KGaA commenced business in 1889 in Lübeck, Germany, and has since developed into a global concern represented in more than a hundred countries. Draeger Safety Pacific represents Dräger’s safety technology in Australia, New Zealand, Papua New Guinea and numerous Pacific Islands.
                                          
Dräger Safety develops, produces, sells and services equipment and systems worldwide which, in addition to assisting human respiration, are designed to monitor and protect life-supporting functions while at the same time creating better and safer conditions for the environment.

Products supplied and supported in the domestic market include:
•    fixed and portable gas detection equipment
•    respiratory masks and filters
•    breathing apparatus and test equipment
•    chemical protection suits
•    decompression chambers and diving systems
•    breathing air compressors
•    breath alcohol and drug testing devices
•    confined space entry equipment
•    mobile and stationary training galleries
•    rental equipment

GlaxoSmithKline

Presentation

Dr Olga Bakharevski
www.gsk.com.au

GlaxoSmithKline (GSK) Australia is one of Australia 's largest pharmaceutical and healthcare companies which is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

GSK Australia plays a significant role in the global pharmaceutical supply chain - exporting in excess of 70% of production to more than 78 countries. Operating from its four main locations in Australia , GSK employs more than 1500 people. It is Australia 's largest supplier of vaccines and a leading supplier of medicines for asthma, bacterial and viral infections, depression, migraine, gastroenterological disease, epilepsy, smoking cessation and pain relief. More than 16 million Australians rely on at least one of GSK's medicines, vaccines or consumer healthcare products. The company invested more than $44 million in R&D in 2006, making it one of Australia 's top 20 R&D investors.

A supplier of antiviral medicines for pandemic preparedness stockpiling by governments, corporations and organisations globally, in 2006 GSK Australia commissioned two lines to manufacture antiviral medication for global distribution to further assist Governments' in pandemic influenza planning and meet antiviral stockpiling demand.

GSK is also a major supplier of seasonal influenza vaccine around the world, and is currently developing an adjuvanted pre-pandemic vaccine for H5N1 avian influenza. In June 2007, GSK announced its intention to donate 50 million doses of H5N1 adjuvanted pre-pandemic influenza vaccine to the World Health Organization (WHO) in support of its stockpile initiative. The donation will help establish a much needed stockpile of pre-pandemic vaccines that can be distributed to the world's poorest countries at short notice by the WHO. Delivered over a three-year period, it will provide enough doses of vaccine for 25 million people at 2 injections per person.

Pandemic Workplace Education

Presentation

www.pandemic.net.au

Pandemic Workplace Education (PWE) provides an online pandemic preparation course that teaches practical measures to help prepare all staff for a pandemic influenza outbreak.  This short 25 minute online course is written in conjunction with doctors and specialists from the Australian Homeland Security Research Centre. The course answers the following questions:

• What is pandemic Influenza?
• How can I protect myself and others?
• What social behavioral, personal hygiene and social distancing measures are recommended?
• What are the signs and symptoms of pandemic influenza?
• What is the Australian Government doing?

          
Also included in the course are 15 downloads including practical exercises, cleaning product information and preventive measures on how to reduce the chances of infection.

• MP3 (3 Meg)

How did employees, employers, customers and the public respond before, during and after the SARS experience?
• Hacy Tobias, former Human Resources Director, Asia Pacific for SAS one of the worlds’ largest software companies (Currently with Strategic Value Management)
• Dr Barry Gilbert, Public Health Management
• Balbir Singh, worked for 3M in Singapore during the SARS outbreak (Currently
Technical Manager for 3M Australia’s Medical and Dental Division)

Converting the ACT Pandemic Plan into reality
Dr Paul Dugdale, ACT Chief Health Officer

Panel on workplace relations and insurance during a pandemic: Compensation for closures, insurance, duty of care, employee entitlements, workers compensation
Panellists
• Alistair Waters, National Secretariat, Community and Public Sector Union
• Dr Jane Romeyn, General Manager, Research and Strategy, Comcare
• Kevin Le Plastrier, Divisional Manager, Corporate Insurance Services, Aon Risk Services Australia Limited
• Ken Pogson, Senior Executive Lawyer, Australian Government Solicitor, Australian Government Solicitor

Case study: Experiences with Pandemic Preparedness in a large Government Department
Christine Bruce, Branch Manager, Business Support Branch, Department of Families, Community Services and Indigenous Affairs and
Stephen Doyle, Principal, Ernst & Young

Case study: Melbourne Fire and Emergency Service Board
Dr Barry Gilbert, Public Health Management
• Pandemic preparations in an essential service organisation (ESO)
• Barriers to being prepared in an ESO
• Challenges to stakeholder consultation
• Introducing hygiene and other behaviour changes

Case study: Pandemic preparation on a university campus
Gaye Cameron, University of NSW

Role Play Scenario
Agency CEO's Address
Agency Influenza Manager’s Address

How to calculate an appropriate stockpile
John Hallam, 3M

Who is eligiable